SCHEMBL199093

SCHEMBL199093

COCCNC(=O)c1ccn2c(-c3csc(C4(c5ccc(C(=O)NO)cc5)CCOCC4)n3)c(C)nc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KCNH2 Q12809 1/20 0.40
HDAC4 P56524 2/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC7 Q8WUI4 2/20 0.38
HDAC8 Q9BY41 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
HDAC9 Q9UKV0 2/20 0.38
HDAC5 Q9UQL6 2/20 0.38
KMT2A Q03164 3/20 0.37
AKT1 P31749 3/20 0.36
AKT2 P31751 3/20 0.36
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
F2RL3 Q96RI0 3/20 0.34
HDAC3 O15379 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3352065 0.95 NPC1 (0.43) NPC1RAB9ASMN1; SMN2KCNH2HDAC4
SCHEMBL3356593 0.93 NPC1 (0.42) NPC1RAB9ASMN1; SMN2KCNH2HDAC4
SCHEMBL196470 0.90 POLB (0.43) KCNH2HDAC4HDAC1HDAC7HDAC8
SCHEMBL197808 0.90 AKT1 (0.45) NPC1RAB9ASMN1; SMN2KCNH2HDAC4
SCHEMBL197698 0.90 AKT1 (0.40) SMN1; SMN2KCNH2HDAC4HDAC1HDAC7
SCHEMBL198502 0.89 HDAC1 (0.41) NPC1RAB9ASMN1; SMN2KCNH2HDAC4
SCHEMBL196935 0.88 KCNH2 (0.40) SMN1; SMN2KCNH2HDAC4HDAC1HDAC7
SCHEMBL3354824 0.88 POLB (0.44) KCNH2HDAC4HDAC1HDAC7HDAC8
SCHEMBL197595 0.88 KCNH2 (0.38) KCNH2HDAC4HDAC1HDAC7HDAC8
SCHEMBL3352933 0.86 POLB (0.43) KCNH2HDAC4HDAC1HDAC7HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088771-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US claimed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 NPC1 277/4885RAB9A 2514/4885SMN1; SMN2 3414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.